Please login to the form below

Not currently logged in
Email:
Password:

BioMarin marketing partner submits BLA in Japan for Naglazyme

BioMarin's co-marketing and distribution partner in Japan, AnGes MG, submits a Biologics License Application for the Maroteaux-Lamy syndrome treatment Naglazyme in Japan

US-headquartered BioMarin Pharmaceutical has said that its co-marketing and distribution partner in Japan, AnGes MG, has submitted a Biologics License Application (BLA) for the Maroteaux-Lamy syndrome (MPS VI) orphan drug treatment Naglazyme (galsulfase) to the Japanese Ministry of Health, Labour and Welfare.

MPS VI is a potentially fatal genetic disease caused by a deficiency of the enzyme N-acetylgalactosamine 4-sulfatase. A deficiency in the enzyme leads to the accumulation of certain complex carbohydrates in the cells of the body giving rise to progressive tissue and organ system damage and eventual failure. The majority of individuals with MPS VI die from disease-related complications between childhood and early adulthood.

BioMarin established a marketing and distribution agreement with AnGes in December 2006, where AnGes obtained exclusive rights to market Naglazyme on the Japanese market.

Naglazyme was approved by the FDA in May 2005 and by the European Commission (EC) in January 2006. As the first drug approved for MPS VI, the FDA and EC have both designated Naglazyme as an orphan drug, ensuring seven years of market exclusivity in the US and 10 years in the EU. The drug also obtained orphan designation in June 2007 from the Ministry of Health, Labour and Welfare (MHLW) in Japan.

Stephen Aselage, senior vice-president of global commercial development at BioMarin, said: "Patient advocacy groups and medical societies in Japan have shown a strong interest in Naglazyme, and we are honoured to bring this life-altering therapy to MPS VI patients in the US, the EU and now to other parts of the world."

Q2 FY07 net sales of Naglazyme at BioMarin were USD 20.9m, compared with USD 18.4m for Q1 FY07, an increase of 13.6 per cent. Net sales for H1 FY07 were USD 39.3m, an increase of USD 22m on net sales of USD 17.3m for H1 FY06.

14th August 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics